Abiomed Announces Q4 FY 2016 Revenue of $94.0 Million, Up 39% Over Prior Year


DANVERS, Mass., 2016-05-03 13:00 CEST (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2016 revenue of $94.0 million, an increase of 39% compared to revenue of $67.6 million for the same period of fiscal 2015.  For fiscal year 2016, total revenue was $329.5 million, up 43% compared to revenue of $230.3 million in fiscal year 2015. This revenue exceeds the third quarter upgraded fiscal year guidance of $326 million.

Fourth quarter fiscal 2016 GAAP net income was $11.0 million or $0.24 per diluted share. For the full fiscal year, GAAP net income was $38.1 million or $0.85 per diluted share.

Financial and operating highlights during the fourth quarter of fiscal 2016 include:

  • Fiscal fourth quarter worldwide Impella® heart pump revenue totaled $88.6 million, an increase of 40% compared to revenue of $63.4 million during the same period of the prior fiscal year.  Full year worldwide Impella revenue totaled $310.1 million, up 46% compared to $212.7 million for fiscal 2015. 
  • U.S. Impella heart pump revenue grew 42% to $81.8 million from $57.7 million in the prior fiscal year with U.S. patient usage of the Impella heart pumps up 45%.  Full year U.S. Impella revenue totaled $287.2 million, up 50% compared to $191.5 million in the prior fiscal year.
  • The installed base for Impella 2.5™ heart pumps grew by an additional 19 hospitals, which made initial purchases of Impella heart pumps, bringing the installed customer base to 1,039 sites.  As part of Abiomed's continued Impella CP® heart pump launch, 38 new U.S. hospitals purchased Impella CP, bringing the total number to 826 sites.  
  • The installed base for Impella RP® heart pumps grew by an additional 9 hospitals, bringing the total number to 80 sites.
  • Gross margin for fiscal fourth quarter 2016 was 84.4% compared to 84.0% in the fourth quarter of fiscal 2015.  For the full fiscal year, gross margin was 84.7% compared to 82.7% in the prior year.
  • Income from operations for the fourth quarter of fiscal 2016 was $19.8 million, or 21%  operating margin, compared to $12.4 million, or 18.3% of revenue in the prior year period. For the full fiscal year, income from operations was $65.1 million, or 19.8% of revenue, compared to $28.7 million, or 12.4% of revenue in the prior year.
  • The Company generated $16.9 million in cash, cash equivalents and marketable securities, totaling $213.1 million as of March 31, 2016, compared to $196.2 million at December 31, 2015. The Company currently has no debt. 
  • In the prior year, GAAP net income included an income tax benefit of $86.5 million largely due to the release of the valuation allowance on most of Abiomed’s deferred tax assets. The release of the valuation allowance was a one-time accounting adjustment in the prior year. As such, fourth quarter fiscal 2015 GAAP net income was $98.9 million ($86.5 million driven by one-time adjustment) or $2.24 per diluted share and full fiscal year GAAP net income was $113.7 million or $2.65 per diluted share. As a comparison basis, GAAP income before taxes for the fourth quarter of fiscal 2016 was $20.2 million, as compared to $12.4 million, or a 63% increase over prior year.
  • On April 7, 2016, Abiomed announced that the Impella 2.5, Impella CP and Impella 5.0™ heart pumps received Food & Drug Administration (FDA) pre-market approval (PMA) for cardiogenic shock. In the setting of cardiogenic shock, the Impella therapy stabilizes a patient’s hemodynamics, unloads the left ventricle, perfuses the end organs and per the indication, allows for heart recovery.

“Our performance validates Impella as the new standard of care and Abiomed as one of the fastest growing, GAAP profitable, medical technology companies.  We have a long run-way for growth as today we estimate that we have penetrated only 5% of the total high risk patient population,” said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. “I am proud of our dedicated employees and grateful to our customers that have enabled our company to create a new era of medicine focused on the Field of Heart Recovery.  Fiscal 2017 is positioned to be a fantastic year as we continue to execute our plan with our exclusive regulatory approvals.”

The Company is giving its fiscal year 2017 guidance for total revenues to be in the range of $430 million to $445 million, an increase of 30% to 35% over the prior year. The Company is also giving its fiscal year 2017 guidance for GAAP operating margin to be in the range of 18% to 20%.

The Company will host a conference call to discuss the results at 8 a.m. ET on Tuesday, May 3, 2016. The conference call releasing full quarterly results will be hosted by Michael R. Minogue, Chairman, President and Chief Executive Officer and Michael Tomsicek, Vice President and Chief Financial Officer.

To listen to the call live, please tune into the webcast via or dial (855) 212-2361; the international number is (678) 809-1538.  A replay of this conference call will be available beginning at 11 a.m. ET May 3, 2016 through 11:59 p.m. ET on May 5, 2016. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 75816370.

The ABIOMED logo, ABIOMED, Impella, Impella CP, and Impella RP are registered trademarks of Abiomed, Inc. in the U.S.A. and certain foreign countries. Impella 2.5, Impella 5.0, Impella LD, Recovering hearts. Saving lives., and Protected PCI are trademarks of Abiomed, Inc.

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit:

This release includes forward-looking statements.  These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning.  These forward-looking statements address various matters. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.  Applicable risks and uncertainties include, among others, uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and the risks identified under the heading “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended March 31, 2015 and the Company’s Quarterly Report on Form 10-Q for the quarters ended June 30, 2015, September 30, 2015 and December 31, 2015, each filed with the Securities and Exchange Commission, as well as other information the Company files with the SEC.  We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.  You are encouraged to read our filings with the SEC, available at, for a discussion of these and other risks and uncertainties.  The forward-looking statements in this press release speak only as of the date of this release and the Company undertakes no obligation to update or revise any of these statements.  Our business is subject to substantial risks and uncertainties, including those referenced above.  Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

For further information please contact: 

Ingrid Goldberg,
Director, Investor Relations

Aimee Genzler
Director, Corporate Communications

Abiomed, Inc. and Subsidiaries  
Consolidated Balance Sheets  
(in thousands, except share data)  
    March 31, 2016   March 31, 2015  
Current assets:          
Cash and cash equivalents   $ 48,231     $ 22,401    
Short-term marketable securities     163,822       109,557    
Accounts receivable, net     42,821       31,828    
Inventories     26,740       16,774    
Prepaid expenses and other current assets     6,778       4,479    
Total current assets     288,392       185,039    
Long-term marketable securities     1,000       13,996    
Property and equipment, net     23,184       9,127    
Goodwill     33,003       31,534    
In-process research and development     15,396       14,711    
Long-term deferred tax assets, net     58,534       80,306    
Other assets     4,422       3,654    
Total assets   $ 423,931     $ 338,367    
Current liabilities:          
Accounts payable   $ 9,381     $ 10,389    
Accrued expenses     28,382       21,894    
Deferred revenue     8,778       7,036    
Total current liabilities     46,541       39,319    
Other long-term liabilities     220       183    
Contingent consideration     7,563       6,510    
Long-term deferred tax liabilities     832       795    
Total liabilities     55,156       46,807    
Commitments and contingencies          
Stockholders' equity:          
Class B Preferred Stock, $.01 par value              
Authorized - 1,000,000 shares; Issued and outstanding - none          
Common stock, $.01 par value     426       413    
Authorized - 100,000,000 shares; Issued - 43,973,119 shares at March 31, 2016 and 42,618,717 shares at March 31, 2015;          
Outstanding - 42,596,228 shares at March 31, 2016 and 41,335,773 shares at March 31, 2015          
Additional paid in capital     508,624       465,046    
Accumulated deficit     (99,075 )     (137,222 )  
Treasury stock at cost - 1,376,891 shares at March 31, 2016 and 1,282,944 shares at March 31, 2015     (26,660 )     (19,347 )  
Accumulated other comprehensive loss     (14,540 )     (17,330 )  
Total stockholders' equity     368,775       291,560    
Total liabilities and stockholders' equity   $ 423,931     $ 338,367    
Abiomed, Inc. and Subsidiaries  
Consolidated Statements of Operations  
(in thousands, except per share data)  
  Three Months Ended 
March 31,
  Fiscal Years Ended 
March 31,
  2016   2015   2016   2015  
Product revenue $ 93,951   $   67,550     $ 329,520   $   229,950    
Funded research and development   6       7       23       361    
    93,957       67,557       329,543       230,311    
Costs and expenses:                        
Cost of product revenue   14,663       10,806       50,419       39,945    
Research and development   14,225       9,853       49,759       35,973    
Selling, general and administrative   45,256       34,535       164,261       125,727    
    74,144       55,194       264,439       201,645    
Income from operations   19,813       12,363       65,104       28,666    
Other income:                        
Investment income, net   186       68       395       196    
Other income (expense), net   228       (59 )     339       (97 )  
    414       9       734       99    
Income before income taxes   20,227       12,372       65,838       28,765    
Income tax provision (benefit)   9,229       (86,502 )     27,691       (84,923 )  
Net income $ 10,998   $   98,874     $ 38,147   $   113,688    
Basic net income per share $ 0.26   $   2.40     $ 0.90   $   2.80    
Basic weighted average shares outstanding   42,463       41,168       42,204       40,632    
Diluted net income per share $ 0.24   $   2.24     $ 0.85   $   2.65    
Diluted weighted average shares outstanding   45,112       44,049       44,895       42,858    


One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Aviva Leverages Appian to Deliver on Digital Transformation Initiatives24.10.2017 13:00Pressemelding

With the Appian Platform, Aviva is Anchoring Around the Customer, Removing Complexities and Streamlining Operations RESTON, Va., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) today announced Aviva, the UK's largest insurer and one of Europe's leading providers of life and general insurance, has deployed Appian's low-code platform to execute on its global digital transformation journey. Putting the customer first helps with Aviva's aim to deliver an unparalleled customer experience. Embedded in three key business units, Appian is helping to transform the way Aviva manages 'Life and Pensions,' 'General Insurance,' and 'Accident and Health.' Aviva has created more than 10 enterprise-grade applications on the Appian platform with a focus on automating processes, streamlining back office operations and creating a single customer view - decreasing operating costs as a result. The company has also digitized pension operations, modernized new produc

eGain Virtual Assistant(TM) named KMWorld Trend-Setting Product for second year in a row24.10.2017 12:30Pressemelding

Solution recognized for delivering a connected, conversational experience SUNNYVALE, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of customer engagement solutions, today announced that its AI-powered solution, eGain Virtual Assistant(TM), has been named in KMWorld Magazine's list of Trend-Setting Products of 2017. Sandra Haimila, Editor at KMWorld, said, "Each year KMWorld looks for software products that break new territory in helping organizations leverage knowledge to achieve their business goals. These products are designed, developed and perfectly timed to fill a niche in the marketplace often before users are even aware that they need such tools." eGain Virtual Assistant is a trend-setter especially because of its integration with human-assisted touchpoints, according to Haimila. Solution highlights: Assists with broad range of inquiries - informational, transactional, and advisory

Dahua Technology H.265 Wi-Fi Cameras A26/C26 Serves Consumer Market24.10.2017 12:26Pressemelding

HANGZHOU, China, Oct. 24, 2017 (GLOBE NEWSWIRE) -- To better serve consumer users, Dahua Technology, a leading solution provider in the global video surveillance industry, released its H.265 Consumer Series products earlier this year. It is now available to most of its markets globally. Below are the details about 2 selected cameras - the indoor cube model C26 and the Pan& Tilt model A26. In an era when people are less and less at home, they are in urgent need of a way to stay connected to it. A26/C26 came along to solve the problem. C26 supports intelligent Human Detection and instant alert, keeping consumers aware of what is going on at home any time they want. Smart Tracking of A26/A46 automatically tracks and keeps tracking any moving object around the camera. Feature Highlights: Fluent High-resolution Video based upon H.265 With 2MP image sensor, A26/C26 delivers crystal clear image. The late

Corporate R&D spending hits record highs for the Top 1000, despite concerns of economic protectionism24.10.2017 08:00Pressemelding

Annual worldwide R&D spending breaks through $700bn for the top 1000 corporate R&D spenders for first time 25% of executives surveyed reported having already experienced some pressure to change how or where they conduct innovation Amazon is the world's largest corporate spender on R&D at over $16bn Alphabet surpasses Apple, according to a global survey of R&D executives, as the Most Innovative Company and for the first time a Chinese company, Alibaba joins the Top 10 Most Innovative Companies list NEW YORK, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Annual worldwide corporate R&D spending broke through $700bn in annual investment, according to an annual analysis of R&D spending across 1000 global public companies by P

TEAM Industries Announces New Innovative Transmission Incorporating Fallbrook's NuVinci® CVP Technology24.10.2017 02:25Pressemelding

Design is ready for vehicle implementation in powered recreational and utility vehicles CEDAR PARK, TEXAS and BAGLEY, MINNESOTA, Oct. 23, 2017 (GLOBE NEWSWIRE) -- TEAM Industries (TEAM) and Fallbrook Technologies Inc. (Fallbrook) announced today that TEAM has a production-ready innovative new transmission design for all-terrain vehicles (ATV) and utility task vehicles (UTV) available to OEMs for vehicle implementation. The transmission incorporates Fallbrook's NuVinci® continuously variable planetary (CVP) technology. NuVinci is a platform technology for a new class of continuously variable transmissions (CVT). It utilizes spheres instead of gears or belts, and can be deployed in a wide variety of applications to improve performance and/or system efficiency. TEAM has an exclusive licensing agreement with Fallbrook for the use of NuVinci CVP technology in North America and Europe in electric and gasoline light vehicle applications. TEAM is also workin

Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging24.10.2017 01:00Pressemelding

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, Company), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR), is pleased to announce that it has entered into a development and commercialization partnership with Advanced Nuclear Medicine Ingredients SA (ANMI). Under the terms of the agreement, Telix and ANMI will partner to commercialise ANMI's 68Ga-HBED-CC-PSMA (68Ga-PSMA-11) kit (Kit), a proven technology used to accurately image and stage metastatic prostate cancer, in the US market. Telix will also offer the Kit on a worldwide basis as a companion diagnostic imaging agent to the Company's prostate cancer therapeutic (TLX-591)1. The agreement includes filing a Drug Master File (DMF) for the Kit, and completion of the necessary clinical trials to obtain marketing authorisatio

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom